432 filings
6-K
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
6-K
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
6-K
GLPG
Galapagos NV
29 Mar 24
Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
6:14am
20-F
2023 FY
GLPG
Galapagos NV
Annual report (foreign)
28 Mar 24
4:02pm
6-K
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
25zg0i6fubt
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
SC 13G/A
pg6g9pl 1eznmae7yr
14 Feb 24
GALAPAGOS / EcoR1 Capital ownership change
5:41pm
SC 13G/A
orwrlx ouj6ovj2t4u
9 Feb 24
GALAPAGOS / FMR ownership change
9:03am
6-K
dmc8 o01c
6 Feb 24
Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
6:00am
6-K
fmi40v hl9
4 Jan 24
Current report (foreign)
5:32pm
6-K
yfougd9
4 Jan 24
Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
4:07pm
6-K
fuxfd5wnzqf
4 Jan 24
Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
4:05pm
6-K
3e21amwd
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
v08e zm2sxk
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
1js0etbek99hha
12 Dec 23
Current report (foreign)
6:00am
S-8
jgosi7rb
4 Dec 23
Registration of securities for employees
5:16pm
6-K
uol98m4
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
adaedxzq yr7t4
2 Nov 23
Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma
7:15am
6-K
0k8is4q6pimey 8x
20 Sep 23
Galapagos appoints Simon Sturge to its Board of Directors
6:00am
6-K
amf2 e3zwo
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am